Published in Cancer Res on January 15, 2007
A review: inflammatory process in Alzheimer's disease, role of cytokines. ScientificWorldJournal (2012) 2.03
Perspectives for cancer prevention with natural compounds. J Clin Oncol (2009) 1.99
Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cells. Expert Rev Vaccines (2007) 1.50
Nanog signaling in cancer promotes stem-like phenotype and immune evasion. J Clin Invest (2012) 1.37
Inflammaging as a prodrome to Alzheimer's disease. J Neuroinflammation (2008) 1.29
Pretreatment with cisplatin enhances E7-specific CD8+ T-Cell-mediated antitumor immunity induced by DNA vaccination. Clin Cancer Res (2008) 1.29
Therapeutic human papillomavirus vaccines: current clinical trials and future directions. Expert Opin Biol Ther (2008) 1.24
Immunotherapy for cervical cancer: Research status and clinical potential. BioDrugs (2010) 1.18
Therapeutic HPV DNA vaccines. Immunol Res (2010) 1.12
DNA vaccines delivered by human papillomavirus pseudovirions as a promising approach for generating antigen-specific CD8+ T cell immunity. Cell Biosci (2011) 1.11
Treatment with proteasome inhibitor bortezomib enhances antigen-specific CD8+ T-cell-mediated antitumor immunity induced by DNA vaccination. J Mol Med (Berl) (2008) 1.04
DNA vaccines for cervical cancer: from bench to bedside. Exp Mol Med (2007) 1.02
Chitosan hydrogel containing GMCSF and a cancer drug exerts synergistic anti-tumor effects via the induction of CD8+ T cell-mediated anti-tumor immunity. Clin Exp Metastasis (2008) 0.99
Emerging human papillomavirus vaccines. Expert Opin Emerg Drugs (2012) 0.96
Immunologic treatments for precancerous lesions and uterine cervical cancer. J Exp Clin Cancer Res (2014) 0.96
Antigen-specific immunotherapy of cervical and ovarian cancer. Immunol Rev (2008) 0.96
Cluster intradermal DNA vaccination rapidly induces E7-specific CD8+ T-cell immune responses leading to therapeutic antitumor effects. Gene Ther (2008) 0.95
Combination of treatment with death receptor 5-specific antibody with therapeutic HPV DNA vaccination generates enhanced therapeutic anti-tumor effects. Vaccine (2008) 0.90
Therapeutic HPV DNA vaccines. Expert Rev Vaccines (2009) 0.90
DNA vaccines for cervical cancer. Am J Transl Res (2010) 0.88
Combination of apigenin treatment with therapeutic HPV DNA vaccination generates enhanced therapeutic antitumor effects. J Biomed Sci (2009) 0.88
Botanicals for the prevention and treatment of cutaneous melanoma. Pigment Cell Melanoma Res (2011) 0.85
Combination of active specific immunotherapy or adoptive antibody or lymphocyte immunotherapy with chemotherapy in the treatment of cancer. Cancer Immunol Immunother (2008) 0.84
Role of Viral miRNAs and Epigenetic Modifications in Epstein-Barr Virus-Associated Gastric Carcinogenesis. Oxid Med Cell Longev (2016) 0.84
Therapeutic targeting of replicative immortality. Semin Cancer Biol (2015) 0.83
LAH4 enhances CD8+ T cell immunity of protein/peptide-based vaccines. Vaccine (2011) 0.83
Green tea polyphenol epigallocatechin-3-gallate suppresses melanoma growth by inhibiting inflammasome and IL-1β secretion. Biochem Biophys Res Commun (2011) 0.83
Scutellaria extract and wogonin inhibit tumor-mediated induction of T(reg) cells via inhibition of TGF-β1 activity. Cancer Immunol Immunother (2011) 0.82
Enhancement of protein vaccine potency by in vivo electroporation mediated intramuscular injection. Vaccine (2010) 0.80
Green and black tea in relation to gynecologic cancers. Mol Nutr Food Res (2011) 0.79
Use of positron emission tomography for real-time imaging of biodistribution of green tea catechin. PLoS One (2014) 0.79
Current state in the development of candidate therapeutic HPV vaccines. Expert Rev Vaccines (2016) 0.79
Treatment with mANT2 shRNA enhances antitumor therapeutic effects induced by MUC1 DNA vaccination. Mol Ther (2010) 0.79
Induction of cellular and molecular immunomodulatory pathways by vitamin A and flavonoids. Expert Opin Biol Ther (2015) 0.77
Over-expressing Akt in T cells to resist tumor immunosuppression and increase anti-tumor activity. BMC Cancer (2015) 0.77
Analysis of the effect of the active compound of green tea (EGCG) on the proliferation of peripheral blood mononuclear cells. BMC Complement Altern Med (2014) 0.76
Enhancement of CD4+ T-cell help reverses the doxorubicin-induced suppression of antigen-specific immune responses in vaccinated mice. Gene Ther (2008) 0.76
Dietary agents in cancer prevention: an immunological perspective. Photochem Photobiol (2012) 0.76
In vivo stepwise immunomodulation using chitosan nanoparticles as a platform nanotechnology for cancer immunotherapy. Sci Rep (2016) 0.75
Catechins and antitumor immunity: Not MDSC's cup of tea. Oncoimmunology (2013) 0.75
Polysaccharides from dioscorea ( shān yào) and other phytochemicals enhance antitumor effects induced by DNA vaccine against melanoma. J Tradit Complement Med (2014) 0.75
Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer (2002) 15.46
Tolerance, danger, and the extended family. Annu Rev Immunol (1994) 14.94
Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med (1998) 7.48
Decoding the patterns of self and nonself by the innate immune system. Science (2002) 7.19
Clinical translation of angiogenesis inhibitors. Nat Rev Cancer (2002) 6.58
Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol (2001) 6.20
Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res (1996) 6.03
Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med (2000) 5.62
CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol (2004) 5.02
Tea catechins and polyphenols: health effects, metabolism, and antioxidant functions. Crit Rev Food Sci Nutr (2003) 3.75
Reversal of immunological tolerance by cyclophosphamide through inhibition of suppressor cell activity. Nature (1974) 3.38
Targeting multiple signaling pathways by green tea polyphenol (-)-epigallocatechin-3-gallate. Cancer Res (2006) 3.17
Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res (2000) 2.91
Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J Immunol (2003) 2.81
Inhibition of carcinogenesis by tea. Annu Rev Pharmacol Toxicol (2002) 2.80
Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals. Clin Cancer Res (2003) 2.80
Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols. Proc Natl Acad Sci U S A (2001) 2.79
Radiation and the microenvironment - tumorigenesis and therapy. Nat Rev Cancer (2005) 2.65
Tea polyphenols: prevention of cancer and optimizing health. Am J Clin Nutr (2000) 2.52
Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res (2003) 2.50
Green tea constituent epigallocatechin-3-gallate and induction of apoptosis and cell cycle arrest in human carcinoma cells. J Natl Cancer Inst (1997) 2.39
CD4 T cells and their role in antitumor immune responses. J Exp Med (1999) 2.27
Green tea and its polyphenolic catechins: medicinal uses in cancer and noncancer applications. Life Sci (2006) 2.25
How will HPV vaccines affect cervical cancer? Nat Rev Cancer (2006) 2.23
Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of Polyphenon E in healthy individuals. Clin Cancer Res (2005) 2.07
Tumor-specific CD4+ T cells have a major "post-licensing" role in CTL mediated anti-tumor immunity. J Immunol (2000) 2.06
Mechanisms of exogenous antigen presentation by MHC class I molecules in vitro and in vivo: implications for generating CD8+ T cell responses to infectious agents, tumors, transplants, and vaccines. Adv Immunol (1999) 1.82
Dendritic cells strongly boost the antitumor activity of adoptively transferred T cells in vivo. Cancer Res (2004) 1.74
Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins. J Clin Invest (2003) 1.71
Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors. Hum Gene Ther (1999) 1.63
Improving DNA vaccine potency via modification of professional antigen presenting cells. Curr Opin Mol Ther (2003) 1.45
Protective effects of green tea extracts (polyphenon E and EGCG) on human cervical lesions. Eur J Cancer Prev (2003) 1.38
Vaccination to prevent and treat cervical cancer. Hum Pathol (2004) 1.25
Blocking telomerase by dietary polyphenols is a major mechanism for limiting the growth of human cancer cells in vitro and in vivo. Cancer Res (2003) 1.24
Enhancing DNA vaccine potency by combining a strategy to prolong dendritic cell life with intracellular targeting strategies. J Immunol (2003) 1.21
Green tea and tea polyphenols in cancer prevention. Front Biosci (2004) 1.18
Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines. Cancer Res (2001) 1.17
Epigallocatechin gallate attenuates adhesion and migration of CD8+ T cells by binding to CD11b. J Allergy Clin Immunol (2004) 1.13
Mechanisms of cancer prevention by green and black tea polyphenols. Anticancer Agents Med Chem (2006) 1.09
Tumor-activated prodrugs--a new approach to cancer therapy. Cancer Invest (2004) 1.09
Cutting edge: tumor-specific CTL are constitutively cross-armed in draining lymph nodes and transiently disseminate to mediate tumor regression following systemic CD40 activation. J Immunol (2004) 1.01
Development of HPV vaccines for HPV-associated head and neck squamous cell carcinoma. Crit Rev Oral Biol Med (2003) 1.01
DNA vaccines for cancer. IDrugs (2003) 1.00
Epigallocatechin gallate induces apoptosis of monocytes. J Allergy Clin Immunol (2005) 0.90
Transglutaminase 2 inhibits Rb binding of human papillomavirus E7 by incorporating polyamine. EMBO J (2003) 0.88
Antigen-specific cancer immunotherapy using a GM-CSF secreting allogeneic tumor cell-based vaccine. Int J Cancer (2000) 0.85
In vivo anti-tumor effect through the controlled release of cisplatin from biodegradable gelatin hydrogel. J Control Release (2003) 0.83
Control of cancers by combining antiangiogenesis and cancer immunotherapy. Drugs Today (Barc) (2005) 0.81
Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA (2013) 5.71
Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med (2012) 3.54
Regulation of tumor angiogenesis by EZH2. Cancer Cell (2010) 3.10
Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res (2013) 2.81
How will HPV vaccines affect cervical cancer? Nat Rev Cancer (2006) 2.23
Diagnostic ability of optical coherence tomography with a normative database to detect localized retinal nerve fiber layer defects. Ophthalmology (2005) 2.03
Cystic lymph node metastasis in patients with head and neck cancer: An HPV-associated phenomenon. Head Neck (2008) 1.97
Comparison of HPV DNA vaccines employing intracellular targeting strategies. Gene Ther (2004) 1.72
Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins. J Clin Invest (2003) 1.71
Cell surface-binding motifs of L2 that facilitate papillomavirus infection. J Virol (2003) 1.68
Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6. J Virol (2004) 1.66
Human papillomavirus-related carcinomas of the sinonasal tract. Am J Surg Pathol (2013) 1.63
Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma. Clin Cancer Res (2006) 1.62
A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression. Nat Med (2005) 1.61
Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe. Vaccine (2003) 1.56
Application of the hybrid capture 2 assay to squamous cell carcinomas of the head and neck: a convenient liquid-phase approach for the reliable determination of human papillomavirus status. Cancer Cytopathol (2011) 1.54
Real-time quantitative PCR demonstrates low prevalence of human papillomavirus type 16 in premalignant and malignant lesions of the oral cavity. Clin Cancer Res (2002) 1.53
Prospects of RNA interference therapy for cancer. Gene Ther (2006) 1.52
Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cells. Expert Rev Vaccines (2007) 1.50
FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal. J Clin Invest (2016) 1.45
The impact of molecular testing on the surgical management of patients with thyroid nodules. Ann Surg Oncol (2014) 1.43
Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles. Neoplasia (2011) 1.42
Control of mesothelin-expressing ovarian cancer using adoptive transfer of mesothelin peptide-specific CD8+ T cells. Gene Ther (2007) 1.40
Ectopic expression of vascular cell adhesion molecule-1 as a new mechanism for tumor immune evasion. Cancer Res (2007) 1.39
The anti-aging gene KLOTHO is a novel target for epigenetic silencing in human cervical carcinoma. Mol Cancer (2010) 1.39
Varying DNA base-pair size in subangstrom increments: evidence for a loose, not large, active site in low-fidelity Dpo4 polymerase. Biochemistry (2006) 1.38
Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery. Vaccine (2009) 1.38
DNA vaccines encoding Ii-PADRE generates potent PADRE-specific CD4+ T-cell immune responses and enhances vaccine potency. Mol Ther (2007) 1.37
Nanog signaling in cancer promotes stem-like phenotype and immune evasion. J Clin Invest (2012) 1.37
EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma. J Natl Cancer Inst (2009) 1.37
Loss of cryptochrome reduces cancer risk in p53 mutant mice. Proc Natl Acad Sci U S A (2009) 1.35
Modification of professional antigen-presenting cells with small interfering RNA in vivo to enhance cancer vaccine potency. Cancer Res (2005) 1.32
Focus on endometrial and cervical cancer. Cancer Cell (2004) 1.32
Generation and characterization of DNA vaccines targeting the nucleocapsid protein of severe acute respiratory syndrome coronavirus. J Virol (2004) 1.30
Pretreatment with cisplatin enhances E7-specific CD8+ T-Cell-mediated antitumor immunity induced by DNA vaccination. Clin Cancer Res (2008) 1.29
Prognostic significance of human papillomavirus in oropharyngeal squamous cell carcinomas. Laryngoscope (2009) 1.27
Chemotherapy acts as an adjuvant to convert the tumor microenvironment into a highly permissive state for vaccination-induced antitumor immunity. Cancer Res (2013) 1.27
Cancer immunotherapy using a DNA vaccine encoding a single-chain trimer of MHC class I linked to an HPV-16 E6 immunodominant CTL epitope. Gene Ther (2005) 1.26
Vaccination to prevent and treat cervical cancer. Hum Pathol (2004) 1.25
Therapeutic human papillomavirus vaccines: current clinical trials and future directions. Expert Opin Biol Ther (2008) 1.24
A DNA vaccine encoding a single-chain trimer of HLA-A2 linked to human mesothelin peptide generates anti-tumor effects against human mesothelin-expressing tumors. Vaccine (2006) 1.24
Enhancement of DNA vaccine potency by coadministration of a tumor antigen gene and DNA encoding serine protease inhibitor-6. Cancer Res (2004) 1.24
Expression of NDRG2 is related to tumor progression and survival of gastric cancer patients through Fas-mediated cell death. Exp Mol Med (2007) 1.24
Vaccinia virus preferentially infects and controls human and murine ovarian tumors in mice. Gene Ther (2006) 1.24
Expression and regulation of NDRG2 (N-myc downstream regulated gene 2) during the differentiation of dendritic cells. FEBS Lett (2003) 1.23
Monitoring the trafficking of adoptively transferred antigen- specific CD8-positive T cells in vivo, using noninvasive luminescence imaging. Hum Gene Ther (2007) 1.23
Management and outcome of bleeding pseudoaneurysm associated with chronic pancreatitis. BMC Gastroenterol (2006) 1.23
Activation of Akt as a mechanism for tumor immune evasion. Mol Ther (2008) 1.22
Assessment of the impact of renal impairment on systemic exposure of new molecular entities: evaluation of recent new drug applications. Clin Pharmacol Ther (2008) 1.22
Enhancing DNA vaccine potency by combining a strategy to prolong dendritic cell life with intracellular targeting strategies. J Immunol (2003) 1.21
Enforced expression of miR-101 inhibits prostate cancer cell growth by modulating the COX-2 pathway in vivo. Cancer Prev Res (Phila) (2011) 1.21
Suppression of NF-kappaB activity by NDRG2 expression attenuates the invasive potential of highly malignant tumor cells. Carcinogenesis (2009) 1.21
Circadian clock control of the cellular response to DNA damage. FEBS Lett (2010) 1.20
A novel adipokine CTRP1 stimulates aldosterone production. FASEB J (2008) 1.20
Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: a clinical trial. J Immunother (2005) 1.19
Human papillomavirus-related carcinoma with adenoid cystic-like features: a peculiar variant of head and neck cancer restricted to the sinonasal tract. Am J Surg Pathol (2013) 1.19
NDRG2 suppresses cell proliferation through down-regulation of AP-1 activity in human colon carcinoma cells. Int J Cancer (2009) 1.18
Immunotherapy for cervical cancer: Research status and clinical potential. BioDrugs (2010) 1.18
Cancer immunotherapy using Sindbis virus replicon particles encoding a VP22-antigen fusion. Hum Gene Ther (2002) 1.17
Berberine-induced AMPK activation inhibits the metastatic potential of melanoma cells via reduction of ERK activity and COX-2 protein expression. Biochem Pharmacol (2011) 1.17
Control of human mesothelin-expressing tumors by DNA vaccines. Gene Ther (2007) 1.17
A chitosan hydrogel-based cancer drug delivery system exhibits synergistic antitumor effects by combining with a vaccinia viral vaccine. Int J Pharm (2007) 1.16
A core human primary tumor angiogenesis signature identifies the endothelial orphan receptor ELTD1 as a key regulator of angiogenesis. Cancer Cell (2013) 1.15
Adiponectin-activated AMPK stimulates dephosphorylation of AKT through protein phosphatase 2A activation. Cancer Res (2009) 1.15
HPV analysis in distinguishing second primary tumors from lung metastases in patients with head and neck squamous cell carcinoma. Am J Surg Pathol (2012) 1.14
Is TKA using patient-specific instruments comparable to conventional TKA? A randomized controlled study of one system. Clin Orthop Relat Res (2013) 1.13
Cancer vaccination drives Nanog-dependent evolution of tumor cells toward an immune-resistant and stem-like phenotype. Cancer Res (2012) 1.13
Generation and characterization of a preventive and therapeutic HPV DNA vaccine. Vaccine (2007) 1.12
Bone morphogenetic protein-4 induced by NDRG2 expression inhibits MMP-9 activity in breast cancer cells. Biochem Biophys Res Commun (2009) 1.12
Therapeutic HPV DNA vaccines. Immunol Res (2010) 1.12